These results are noteworthy, given that a similar inhibitor of the IRE1α RNase domain, named ORIN1001, is currently undergoing clinical trials in patients with cancer (ClinicalTrials.gov identifier: NCT03950570) and pulmonary fibrosis (ClinicalTrials.gov identifier: NCT04643769). The gene discussed is ERN1; the disease is pulmonary fibrosis.